The Human Hookworm Vaccine

被引：82

作者：

Hotez, Peter J. ^{[1
,2
,3
,4
]}

Diemert, David ^{[1
,2
,5
]}

Bacon, Kristina M. ^{[6
]}

Beaumier, Coreen ^{[1
,2
,3
,4
]}

Bethony, Jeffrey M. ^{[1
,2
,5
]}

Bottazzi, Maria Elena ^{[1
,2
,3
,4
]}

Brooker, Simon ^{[7
]}

Couto, Artur Roberto ^{[8
]}

Freire, Marcos da Silva ^{[8
]}

Homma, Akira ^{[8
]}

Lee, Bruce Y. ^{[6
]}

Loukas, Alex ^{[9
]}

Loblack, Marva ^{[1
,2
]}

Morel, Carlos Medicis ^{[8
]}

Oliveira, Rodrigo Correa ^{[10
]}

Russell, Philip K. ^{[1
,2
]}

机构：

[1] Sabin Vaccine Inst Prod Dev Partnership, Houston, TX USA

[2] Sabin Vaccine Inst Prod Dev Partnership, Washington, DC USA

[3] Sabin Vaccine Inst, Houston, TX USA

[4] Texas Childrens Hosp, Baylor Coll Med, Ctr Vaccine Dev, Natl Sch Trop Med, Houston, TX 77030 USA

[5] George Washington Univ, Sch Med & Hlth Sci, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA

[6] Univ Pittsburgh, Sch Med, Publ Hlth Computat & Operat Res PHICOR, Pittsburgh, PA USA

[7] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England

[8] Fiocruz MS, Oswaldo Cruz Fdn, BR-21045900 Rio De Janeiro, Brazil

[9] James Cook Univ, Queensland Trop Hlth Alliance, Cairns, Australia

[10] Fiocruz MS, Oswaldo Cruz Fdn, Rene Rachou Res Ctr, Belo Horizonte, MG, Brazil

来源：

VACCINE | 2013年 / 31卷

基金：

比尔及梅琳达.盖茨基金会;

关键词：

Hookworm; Helminth; Na-GST-1; Na-APR-1; Anemia; NEUTRALIZING ANTIBODIES; INFECTION; MEBENDAZOLE; EFFICACY; ANEMIA; HEMOGLOBINASE; ALBENDAZOLE; POPULATIONS; CANDIDATE; BILLION;

D O I：

10.1016/j.vaccine.2012.11.034

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Hookworm infection is one of the world's most common neglected tropical diseases and a leading cause of iron deficiency anemia in low- and middle-income countries. A Human Hookworm Vaccine is currently being developed by the Sabin Vaccine Institute and is in phase 1 clinical testing. The candidate vaccine is comprised of two recombinant antigens known as Na-GST-1 and Na-APR-1, each of which is an important parasite enzyme required for hookworms to successfully utilize host blood as a source of energy. The recombinant proteins are formulated on Alhydrogel (R) and are being tested in combination with a synthetic Toll-like receptor 4 agonist. The aim of the vaccine is to induce anti-enzyme antibodies that will reduce both host blood loss and the number of hookworms attached to the gut. Transfer of the manufacturing technology to the Oswaldo Cruz Foundation (FIOCRUZ)/Bio-Manguinhos (a Brazilian public sector developing country vaccine manufacturer) is planned, with a clinical development plan that could lead to registration of the vaccine in Brazil. The vaccine would also need to be introduced in the poorest regions of Africa and Asia, where hookworm infection is highly endemic. Ultimately, the vaccine could become an essential tool for achieving hookworm control and elimination, a key target in the 2012 London Declaration on Neglected Tropical Diseases. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：B227 / B232

页数：6

共 37 条

[1]

Albonico M, 2003, B WORLD HEALTH ORGAN, V81, P343

[2] RATE OF REINFECTION WITH INTESTINAL NEMATODES AFTER TREATMENT OF CHILDREN WITH MEBENDAZOLE OR ALBENDAZOLE IN A HIGHLY ENDEMIC AREA [J].